Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ZeroStack Corp. (ZSTK)
USD2.04
+0.22 (+12.35%)
CA NASDAQ Healthcare Medical - Distribution
Address
40 King Street West M5H 3Y2
Toronto, ON, CA
Toronto, ON, CA
CEO
Daniel Reis-Faria
Website
zerostack.ai
IPO
2021-05-11
CIK 1790169 ISIN CA98956L1013
Also trades on
NASDAQ Capital Market · FLGC (USD)
NASDAQ Global Market · ZSTK (USD)
Description
ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens. In addition, the company invests in early-stage companies. The company was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026. ZeroStack Corp. was incorporated in 2019 and is based in Toronto, Canada.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.04
+0.22 (+12.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.5K
Beta
1.78
Float Shares
836.0K
Free Float %
79.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.75% | +8.16% | -22.15% | -42.72% | -43.83% | -25.88% | -81.41% | -97.47% | -99.85% | -99.88% | -99.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
2.04
Low
30.00
+1,367.2%
Consensus
185.00
+8,947.8%
Median
185.00
+8,947.8%
High
340.00
+16,528.4%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
30.00
+1,367.2%
|
| All Time | 3 |
125.67
+6,046.1%
|
Quality scores
Altman Z-Score
-9.24
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-40.1% Q1'26: -38.3% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-3,245.4% Q1'26: +7.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-19.5% Q1'26: -52.9% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-26.8% Q1'26: -17.1% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-8.0% Q1'26: -13.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%-77.6% ★ Q1'26: +5,123.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-6.01× Q1'26: -0.72× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
59.51M
est: 59.70M (-0.3%)
|
35.68M
est: 61.94M (-42.4%)
|
40.50M
40.50M – 40.50M
-34.6% YoY
|
| EBITDA |
-15.10M
est: -31.56M (+52.2%)
|
-8.98M
est: -32.75M (+72.6%)
|
-21.41M
-21.41M – -21.41M
+34.6% YoY
|
| EBIT |
-15.87M
est: -33.22M (+52.2%)
|
-9.56M
est: -34.47M (+72.3%)
|
-22.54M
-22.54M – -22.54M
+34.6% YoY
|
| Net Income |
-15.91M
est: -99.85M (+84.1%)
|
-120.85M
est: -5.02M (-2,309.4%)
|
-1.79M
-1.79M – -1.79M
+64.3% YoY
|
| SGA |
23.08M
est: 42.59M (-45.8%)
|
1.21M
est: 44.19M (-97.3%)
|
28.90M
28.90M – 28.90M
-34.6% YoY
|
| EPS |
-1.30
est: -36.27 (+96.4%)
|
-43.49
est: -1.82 (-2,287.0%)
|
-0.65
-0.65 – -0.65
+64.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.02M
OE per share TTM
-10.01
Owner's Yield
-23.86%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
6.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
397.3K
Insider transactions (90d)
3
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
+9 vs prev Q
New positions
9
Closed positions
0
Increased
9
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 25.4K +25.4K (+100.0%) | 157.2K +157.2K (+100.0%) | 0.26% +0.256 pp | 0.00% +0.000 pp | USD6.18 +0.0% | 1 qtrs NEW |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 25.3K +25.3K (+100.0%) | 156.5K +156.5K (+100.0%) | 0.25% +0.254 pp | 0.00% +0.000 pp | USD6.18 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD FIDUCIARY TRUST CO | 12.6K +12.6K (+100.0%) | 78.2K +78.2K (+100.0%) | 0.13% +0.127 pp | 0.00% +0.000 pp | USD6.18 +0.0% | 1 qtrs NEW |
| 4 | UBS GROUP AG | 666.00 +666.0 (+100.0%) | 4.1K +4.1K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD6.18 +0.0% | 1 qtrs NEW |
| 5 | MORGAN STANLEY | 173.00 +173.0 (+100.0%) | 1.1K +1.1K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD6.18 +0.0% | 1 qtrs NEW |
| 6 | BERNARD WEALTH MANAGEMENT CORP. | 12.00 +12.0 (+100.0%) | 75.00 +75.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.17 +0.2% | 1 qtrs NEW |
| 7 | ADVISOR GROUP HOLDINGS, INC. | 12.00 +12.0 (+100.0%) | 73.00 +73.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.17 +0.2% | 1 qtrs NEW |
| 8 | SOUND INCOME STRATEGIES, LLC | 12.00 +12.0 (+100.0%) | 72.00 +72.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.17 +0.2% | 1 qtrs NEW |
| 9 | KEY FINANCIAL INC | 1.00 +1.0 (+100.0%) | 6.00 +6.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 +3.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 111.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
98.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+98,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Zeifman Laurence | Director | A-Award | A | Director Stock Option ("Right to Buy") | 28,000 | 5.10 | 142.8K | 28,000 | D | ↗ |
| 2026-05-05 | WOO EDWARD | Director | A-Award | A | Director Stock Option ("Right to Buy") | 35,000 | 5.10 | 178.5K | 35,000 | D | ↗ |
| 2026-05-05 | LEVENTHAL MANFRED | Director | A-Award | A | Director Stock Option ("Right to Buy") | 35,000 | 5.10 | 178.5K | 35,000 | D | ↗ |
| 2026-03-31 | Heinrich Michael | Director / Officer | J-Other | D | Convertible Promissory Note | 4,902,220 | 33.34 | 163.44M | 0 | I | ↗ |
| 2026-01-06 | Zeifman Laurence | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-19 | Vaiman Dany | Officer | A-Award | A | Employee Stock Option ("Right to Buy") | 235,604 | 7.31 | 1.72M | 235,604 | D | ↗ |
| 2025-12-19 | Reis-Faria Daniel | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 471,208 | 7.31 | 3.44M | 471,208 | D | ↗ |
| 2025-12-19 | Heinrich Michael | Director / Officer | A-Award | A | Director Stock Option (Right to Buy) | 471,208 | 7.31 | 3.44M | 471,208 | D | ↗ |
| 2025-10-23 | Heinrich Michael | Director / Officer | X-InTheMoney | A | Convertible Promissory Note | 4,902,220 | 33.34 | 163.44M | 4,902,220 | I | ↗ |
| 2025-10-22 | BROWN MICHAEL JOHN | Director | A-Award | A | Deferred Share Units ("DSUs") | 7,468 | 0.00 | — | 94,421 | D | ↗ |
| 2025-10-09 | Reis-Faria Daniel | Director / Officer | P-Purchase | A | Pre-Funded Token Warrants | 5,954,743 | 0.00 | 595.47 | 5,954,743 | D | ↗ |
| 2025-09-20 | Reis-Faria Daniel | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-20 | Heinrich Michael | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-30 | Wolkin Harold | Director | D-Return | D | Stock Appreciation Rights ("SARs") | 30,000 | 1.30 | 39.0K | 0 | D | ↗ |
| 2025-06-30 | Vaiman Dany | Officer | D-Return | D | Stock Appreciation Rights ("SARs") | 191,773 | 0.92 | 175.5K | 0 | D | ↗ |
| 2025-06-30 | Starke Clifford | Director / Officer | D-Return | D | Stock Appreciation Rights ("SARs") | 1,028,665 | 1.21 | 1.24M | 0 | D | ↗ |
| 2025-06-30 | LEVENTHAL MANFRED | Director | D-Return | D | Stock Appreciation Rights ("SARs") | 5,000 | 1.30 | 6.5K | 0 | D | ↗ |
| 2024-12-15 | Wolkin Harold | Director | A-Award | A | Stock Appreciation Rights ("SARs") | 30,000 | 1.30 | 39.0K | 30,000 | D | ↗ |
| 2024-12-15 | WOO EDWARD | Director | A-Award | A | Common Shares | 50,000 | 0.00 | — | 134,698 | D | ↗ |
| 2024-12-15 | Vaiman Dany | Officer | A-Award | A | Stock Appreciation Rights ("SARs") | 372,500 | 1.30 | 484.3K | 372,500 | D | ↗ |
| 2024-12-15 | Starke Clifford | Director / Officer | A-Award | A | Common Shares | 900,000 | 0.00 | — | 906,846 | D | ↗ |
| 2024-12-15 | LEVENTHAL MANFRED | Director | A-Award | A | Stock Appreciation Rights ("SARs") | 5,000 | 1.30 | 6.5K | 5,000 | D | ↗ |
| 2024-12-15 | DORF SAMMY | Director / Officer | A-Award | A | Common Shares | 250,000 | 0.00 | — | 250,000 | D | ↗ |
| 2024-12-05 | LEVENTHAL MANFRED | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-05 | DORF SAMMY | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-13 | Starke Clifford | Director / Officer | P-Purchase | A | Common Shares | 6,795 | 0.95 | 6.5K | 6,846 | — | ↗ |
| 2024-09-06 | Wolkin Harold | Director | P-Purchase | A | Common Shares | 5,000 | 0.96 | 4.8K | 5,000 | — | ↗ |
| 2024-09-05 | Starke Clifford | Director / Officer | P-Purchase | A | Common Shares | 51 | 0.95 | 48.45 | 474,046 | — | ↗ |
| 2024-08-29 | Wolkin Harold | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-14 | Vaiman Dany | Officer | A-Award | A | Stock Appreciation Rights ("SARs") | 191,773 | 0.92 | 175.5K | 191,773 | — | ↗ |
| 2024-08-14 | Starke Clifford | Director / Officer | A-Award | A | Stock Appreciation Rights ("SARs") | 575,319 | 0.92 | 526.4K | 575,319 | — | ↗ |
| 2024-05-02 | CAHILL BRENDAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-08 | Starke Clifford | Director / Officer | P-Purchase | A | Common Shares | 526,315 | 1.90 | 1,000.0K | 565,714 | — | ↗ |
| 2023-12-15 | Vaiman Dany | Officer | A-Award | A | Stock Appreciation Rights ("SARs") | 342,888 | 1.21 | 414.9K | 342,888 | — | ↗ |
| 2023-12-15 | Starke Clifford | Director / Officer | A-Award | A | Stock Appreciation Rights ("SARs") | 1,028,665 | 1.21 | 1.24M | 1,028,665 | — | ↗ |
| 2023-11-15 | WOO EDWARD | Director | A-Award | A | Common Shares | 74,512 | 0.00 | — | 84,698 | — | ↗ |
| 2023-11-15 | Vaiman Dany | Officer | A-Award | A | Common Shares | 149,024 | 0.00 | — | 170,850 | — | ↗ |
| 2023-11-15 | Taylor Kevin | Director / Officer | A-Award | A | Common Shares | 124,186 | 0.00 | — | 124,186 | — | ↗ |
| 2023-11-15 | Starke Clifford | Director / Officer | A-Award | A | Common Shares | 327,851 | 0.00 | — | 473,995 | — | ↗ |
| 2023-11-15 | SOLOMON THOMAS | Director | A-Award | A | Common Shares | 35,766 | 0.00 | — | 35,766 | — | ↗ |
| 2023-07-21 | Garayev Elshad | — | — | D | Options (Right to Buy) | 75,000 | 0.93 | 69.8K | 0 | — | ↗ |
| 2023-07-05 | Konigsberg Brandon | — | — | D | Options (Right to Buy) | 100,000 | 0.93 | 93.0K | 0 | — | ↗ |
| 2023-06-25 | Rakine Hussein | Director | D-Return | D | Common Shares | 82,100 | 0.00 | — | 2,500 | — | ↗ |
| 2023-06-06 | Taylor Kevin | Director | — | I | Common Shares | 0 | 0.00 | — | 14,550 | — | ↗ |
| 2023-06-06 | SOLOMON THOMAS | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-18 | Cohen, Matthew S. | Officer | F-InKind | D | Common Shares | 90,146 | 0.24 | 21.6K | 329,610 | — | ↗ |
| 2023-04-16 | Rakine Hussein | Director / Officer | A-Award | A | Common Shares | 1,200,000 | 0.00 | — | 1,692,019 | — | ↗ |
| 2023-03-17 | WOO EDWARD | Director | A-Award | A | Options (Right to Buy) | 100,000 | 0.35 | 35.0K | 100,000 | — | ↗ |
| 2023-03-17 | Richardson Beverley | Director | A-Award | A | Common Shares | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2023-03-17 | ROA JUAN CARLOS GOMEZ | Director | A-Award | A | Common Shares | 150,000 | 0.00 | — | 2,042,509 | — | ↗ |
| 2023-03-17 | MASTRONARDI MARC | Director | A-Award | A | Common Shares | 150,000 | 0.00 | — | 160,000 | — | ↗ |
| 2023-03-17 | LESLIE JOHN TIMOTHY | Director | A-Award | A | Common Shares | 125,000 | 0.00 | — | 138,574 | — | ↗ |
| 2023-03-17 | Konigsberg Brandon | Director | A-Award | A | Common Shares | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-01 | WOO EDWARD | Director | — | I | Common Shares | 0 | 0.00 | — | 40,419 | — | ↗ |
| 2023-01-01 | WARNOCK JASON | Director | — | D | Common Shares | 0 | 0.00 | — | 335,801 | — | ↗ |
| 2023-01-01 | Vaiman Dany | Director | — | D | Common Shares | 0 | 0.00 | — | 436,529 | — | ↗ |
| 2023-01-01 | Starke Clifford | Director | — | I | Common Shares | 0 | 0.00 | — | 116,407 | — | ↗ |
| 2023-01-01 | Richardson Beverley | Director | — | D | Options (Right to Buy) | 50,000 | 2.04 | 102.0K | — | — | ↗ |
| 2023-01-01 | ROA JUAN CARLOS GOMEZ | Director | — | D | Common Shares | 0 | 0.00 | — | 1,892,509 | — | ↗ |
| 2023-01-01 | MORGAN ANNABELLA MANALO | Director | — | D | Options (Right to Buy) | 200,000 | 2.04 | 408.0K | — | — | ↗ |
| 2023-01-01 | MERCHAN LUIS | Director | — | D | Common Shares | 0 | 0.00 | — | 1,975,149 | — | ↗ |
| 2023-01-01 | MASTRONARDI MARC | Director | — | D | Common Shares | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2023-01-01 | LESLIE JOHN TIMOTHY | Director | — | D | Common Shares | 0 | 0.00 | — | 13,574 | — | ↗ |
| 2023-01-01 | Cohen, Matthew S. | Director | — | D | Common Shares | 0 | 0.00 | — | 419,756 | — | ↗ |
| 2023-01-01 | Casner Jessie | Director | — | D | Common Shares | 0 | 0.00 | — | 219,693 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-455.3K
Shares Outstanding
1.05M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Clifford Starke, former Chief Executive Officer | 420.0K | 36.0K | 2.26M | — | — | — | 2.72M | 83.24% | ↗ |
| 2 | 2024 | Clifford Starke, Chief Executive Officer | 420.0K | 36.0K | 2.26M | — | — | — | 2.72M | 83.24% | ↗ |
| 3 | 2024 | Dany Vaiman, Chief Financial Officer | 275.0K | 18.0K | 819.0K | — | — | 23.8K | 1.14M | 72.11% | ↗ |
| 4 | 2024 | Sammy Dorf, former Executive Chairman | 21.0K | — | 325.0K | — | — | — | 346.0K | 93.94% | ↗ |
| 5 | 2024 | Sammy Dorf, Executive Chairman | 21.0K | — | 325.0K | — | — | — | 346.0K | 93.94% | ↗ |
| 6 | 2023 | Luis Merchan , former Chief Executive Officer | 433.6K | — | 495.0K | — | — | 48.1K | 976.7K | 50.68% | ↗ |
| 7 | 2023 | Clifford Starke, Chief Executive Officer | 371.2K | — | 249.2K | — | — | 8.1K | 628.5K | 39.64% | ↗ |
| 8 | 2023 | Clifford Starke, former Chief Executive Officer | 371.2K | — | 249.2K | — | — | 8.1K | 628.5K | 39.64% | ↗ |
| 9 | 2023 | Hussein Rakine , former Chief Executive Officer | 84.6K | — | 296.4K | — | — | — | 381.0K | 77.79% | ↗ |
| 10 | 2023 | Dany Vaiman, Chief Financial Officer | 243.3K | — | 113.3K | — | — | 23.5K | 380.0K | 29.80% | ↗ |
| 11 | 2023 | Matthew Cohen, former General Counsel | 145.8K | 60.0K | — | — | — | 31.3K | 237.1K | 0.00% | ↗ |
| 12 | 2022 | Luis Merchan , former Chief Executive Officer | 378.3K | — | 540.0K | 101.1K | — | 48.1K | 1.07M | 60.06% | ↗ |
| 13 | 2022 | Luis Merchan, former Chief Executive Officer | 378.3K | — | 540.0K | 101.1K | — | 48.1K | 1.07M | 60.06% | ↗ |
| 14 | 2022 | Matthew Cohen, former General Counsel | 245.8K | 60.0K | 270.0K | 109.4K | — | 31.3K | 716.5K | 52.95% | ↗ |
| 15 | 2022 | Matthew Cohen, General Counsel | 245.8K | 60.0K | 270.0K | 109.4K | — | 31.3K | 716.5K | 52.95% | ↗ |
| 16 | 2022 | Hussein Rakine , former Chief Executive Officer | 216.3K | — | 300.0K | 56.2K | — | — | 572.5K | 62.22% | ↗ |
| 17 | 2022 | James Choe, former Chief Strategy Officer | 265.8K | 22.5K | 230.0K | — | — | — | 518.3K | 44.38% | ↗ |
| 18 | 2022 | Jessie Casner, Chief Marketing Officer | 181.7K | 40.0K | 150.0K | 28.1K | — | — | 399.8K | 44.55% | ↗ |
| 19 | 2022 | Dany Vaiman, Chief Financial Officer | 4.6K | — | — | — | — | 163.0K | 167.6K | 0.00% | ↗ |
| 20 | 2022 | Clifford Starke, Chief Executive Officer | 7.0K | — | 24.3K | — | — | — | 31.3K | 77.60% | ↗ |
| 21 | 2021 | Luis Merchan, former Chief Executive Officer | 326.3K | 419.0K | 1.53M | 189.8K | — | — | 2.47M | 69.77% | ↗ |
| 22 | 2021 | Matthew Cohen, General Counsel | 75.0K | 60.0K | — | 415.9K | — | — | 550.9K | 75.49% | ↗ |
| 23 | 2021 | Jessie Casner, Chief Marketing Officer | 15.0K | — | — | 113.9K | — | — | 128.9K | 88.36% | ↗ |
| 24 | 2021 | James Choe, former Chief Strategy Officer | 11.0K | — | — | 113.9K | — | — | 124.9K | 91.16% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel Reis-Faria | Chief Executive Officer & Director | 880.2K | male |
| Michael Heinrich | Executive Chairman | 869.6K | male |
| Dany Vaiman | Chief Financial Officer | 374.5K | male |
| Aaron Atin | Corporate Secretary | — | male |
| Manfred Ziegler | Managing Director | — | — |
| Patrick Moloney | Head of Product Development | — | male |
ESG Rating
ESG Score History ASSET MANAGEMENT
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ZSTK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
